Current chemotherapeutic options for the treatment of gestational trophoblastic disease

Mortality factors in high and ultra-high-risk gestational trophoblastic neoplasia at moi teaching & referral hospital: A decade-long observation in kenya

“…Early mortality is prevalent among women with ultrahigh-risk disease, usually due to sudden hemorrhage and tumor lysis, indicating a high burden of disease. This can be averted with appropriate and early initiation of chemotherapy as well as low-dose induction chemotherapy ( Braga et al, 2023 Feb ). According to a Dutch central registry, the number of deaths, especially early deaths, associated with the management of women with GTN over four decades has decreased substantially following the introduction of low-dose etoposide and cisplatin (EP) for women with high-risk and heavy disease burdens ( Lybol et al, 2012 ).…”

Immunotherapy in the treatment of chemoresistant gestational trophoblastic neoplasia - systematic review with a presentation of the first 4 Brazilian cases

“…The World Health Organization (WHO) scoring system based on risk factors ( Supplemental Table 2 ) was used to decide the chemotherapy treatment. 1 , 3 Patients diagnosed with WHO/FIGO risk score ≤6 (low-risk GTN) were treated with single-agent chemotherapy (preferably an MTX regimen followed by Actinomycin-D – Act-D or carboplatin, in cases of chemoresistance). Patients diagnosed with FIGO risk score ≥7 (high-risk GTN) received multiagent-chemotherapy (preferably etoposide, MTX, Act-D, cyclophosphamide, oncovin – EMA/CO, followed by etoposide, cisplatin, MTX, Act-D – EP/EMA or paclitaxel/cisplatin-paclitaxel/etoposide – TP/TE regimen in cases of chemoresistance).…”

“…Patients diagnosed with FIGO risk score ≥7 (high-risk GTN) received multiagent-chemotherapy (preferably etoposide, MTX, Act-D, cyclophosphamide, oncovin – EMA/CO, followed by etoposide, cisplatin, MTX, Act-D – EP/EMA or paclitaxel/cisplatin-paclitaxel/etoposide – TP/TE regimen in cases of chemoresistance). 1 , 3 …”

“… 2 Efforts have been made to establish novel treatments for these cases, as well as to lessen the immediate and cumulative side effects of the drugs used to treat GTN. 3 …”

Impacto da distância entre a residência da paciente e o centro de referência nos indicadores clínicos e de qualidade da assistência à saúde prestada às mulheres com neoplasia trofoblástica gestacional no Estado do Rio de Janeiro

“…A origem gestacional dessa neoplasia confere duas características únicas a essa doença: a primeira é exibir um biomarcador tumoral sensível, a gonadotrofina coriônica humana (hCG), capaz de atestar o diagnóstico, o prognóstico, a resposta terapêutica, a remissão e a recivida da NTG. A segunda é o elevado componente genético paterno desses blastomas, o que pode estar associado às excepcionais taxas de cura da NTG, mesmo em casos quimiorresistentes e multimetastáticos 3 .…”